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Abstract
Adrenocortical carcinoma (ACC) is diagnosed using the histopathological Weiss score 
(WS), but remains clinically elusive unless it has metastasized or grows locally invasive. 
Previously, we proposed the objective IGF2 methylation score as diagnostic tool for ACC. 
This multicenter European cohort study validates these findings. Patient and tumor 
characteristics were obtained from adrenocortical tumor patients. DNA was isolated 
from frozen specimens, where after DMR2, CTCF3, and H19 were pyrosequenced. The 
predictive value of the methylation score for malignancy, defined by the WS or metastasis 
development, was assessed using receiver operating characteristic curves and logistic and 
Cox regression analyses. Seventy-six ACC patients and 118 patients with adrenocortical 
adenomas were included from seven centers. The methylation score and tumor size were 
independently associated with the pathological ACC diagnosis (OR 3.756 95% CI  
2.224–6.343; OR 1.467 95% CI 1.202–1.792, respectively; Hosmer–Lemeshow test 
P = 0.903), with an area under the curve (AUC) of 0.957 (95% CI 0.930–0.984). The 
methylation score alone resulted in an AUC of 0.910 (95% CI 0.866–0.952). Cox regression 
analysis revealed that the methylation score, WS and tumor size predicted development 
of metastases in univariate analysis. In multivariate analysis, only the WS predicted 
development of metastasis (OR 1.682 95% CI 1.285–2.202; P < 0.001). In conclusion, we 
validated the high diagnostic accuracy of the IGF2 methylation score for diagnosing ACC 
in a multicenter European cohort study. Considering the known limitations of the WS, the 
objective IGF2 methylation score could potentially provide extra guidance on decisions on 
postoperative strategies in adrenocortical tumor patients.
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Introduction
Adrenal tumors occur at high frequencies in the general 
population and are often detected incidentally. Autopsy 
studies show a prevalence of 1.0–8.7% (Kloos et al. 1995, 
Grumbach et  al. 2003). Radiological studies report a 
frequency of clinically unapparent adrenal masses of less 
than 1% for patients under 30 years of age, a percentage 
which increases up to 10% in those 70 years of age or 
older (Barzon et al. 2003, Bovio et al. 2006, Fassnacht et al. 
2016). Several CT characteristics, like a large diameter 
(>6 cm), lack of a well-defined margin, and increased 
heterogeneity, can point towards a malignant adrenal 
mass, but these collective findings will not always indicate 
a clear differential diagnosis (Nieman 2010). Only in 
rare cases, the adrenal tumor has malignant potential. 
Adrenocortical carcinoma (ACC) is a highly malignant 
tumor with 5-year-survival ranging from 16 to 38% 
(Kebebew et  al. 2006, Fassnacht et  al. 2013). The Weiss 
score (WS), consisting of nine histopathological criteria, 
is the most frequently used scoring system to differentiate 
between benign and malignant adrenocortical tumors 
(Weiss et  al. 1989, Aubert et  al. 2002) and is also 
recommended in the European clinical guidelines on 
ACC (Fassnacht et al. 2018). A tumor is classified as ACC 
at the presence of three or more Weiss criteria. The WS 
can be ambiguous when a score of 2 or 3 is obtained, as 
metastasized cases have been reported with a WS as low as 
2 (Pohlink et al. 2004, Lau & Weiss 2009, Tissier 2010, de 
Krijger & Papathomas 2012). In addition, the WS has been 
challenged due to interobserver variability and subjectivity 
and may be difficult to apply in specific circumstances, 
even for experienced pathologists (Papotti et  al. 2011, 
Tissier et al. 2012). Consequences of malignant disease are 
significant, since prognosis is poor and adjuvant mitotane 
treatment is recommended in ACC patients after curative 
resection, particularly in the case of patients with tumors 
harbouring high recurrence risk (Allolio & Fassnacht 2006, 
Fassnacht et  al. 2018). Research is focusing on bias-free 
molecular markers to identify adrenocortical tumors with 
malignant potential. Since the diagnosis of malignancy 
is clinically elusive in non-metastasizing adrenocortical 
tumors, this can be challenging.
Recently, we showed that methylation patterns of IGF2 
regulatory regions discriminate ACC from adrenocortical 
adenoma (ACA) with a sensitivity of 94% and a specificity 
of 96% (Creemers et  al. 2016b). This IGF2 methylation 
score is based on the most frequent molecular alteration 
in ACC, that is, increased IGF2 expression (Erickson 
et al. 2001, Giordano et al. 2003, de Fraipont et al. 2005, 
Almeida et al. 2008, Wang et al. 2014). The IGF2 gene is 
an imprinted gene whose expression largely varies within 
ACC (Schmitt et al. 2006, Wang et al. 2014). The proposed 
methylation score consists of the mean standard deviation 
score of three different IGF2 regulatory regions compared 
to methylation in normal adrenals (Creemers et al. 2016b). 
The original study, however, only included two limited 
cohorts with a total of 33 ACCs and 27 ACAs. The major 
objective of the present study is to validate the diagnostic 
role of the IGF2 methylation score in a multicenter cohort 
study via the European Network for the Study of Adrenal 
Tumors (ENS@T, www.ensat.org). Second aim is to correlate 
the IGF2 methylation score with follow-up clinical 
characteristics in patients with adrenocortical tumors.
Methods
Patients and data collection
Patients with ACC or ACA from whom DNA from a snap-
frozen specimen from the primary adrenocortical tumor 
was available were included. Inclusion of both ACC and 
ACA was mandatory for each individual center, and cases 
that were included in our previous study investigating 
the IGF2 methylation score were not included in this 
study (Creemers et  al. 2016b). Data collected included: 
age at diagnosis, sex, initial tumor size, steroid secretion 
pattern, the WS with individual parameters, ENSAT tumor 
stage, follow-up duration and clinical status at the end 
of the follow-up period. According to availability at the 
participating centers, frozen specimens or 200 ng DNA 
isolated from frozen specimens were collected at Erasmus 
University Medical Center (EMC). Ten patients had to be 
excluded because of insufficient DNA yield. Diagnosis was 
based on the WS determined by the local pathologists, 
with a threshold of malignancy of ≥3 criteria present in 
the tumor. Two paediatric patients were excluded because 
of uncertain ACC diagnosis based on the WS. Of these 
two patients, no follow-up data were available. This study, 
that uses residual material, was approved by the Medical 
Ethics Committee of the Erasmus Medical Center and 
furthermore inclusion of patients was approved by the 
local ethics committees. Approval for use of tissues for 
research purposes was obtained at the coordinating center.
DNA isolation and pyrosequencing
Processing of adrenocortical tumors and DNA isolation, 
when necessary, was performed as previously described 
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using the Wizard® Genomic DNA Purification Kit 
(Promega), according to manufacturer’s protocol 
(Creemers et al. 2016b). Bisulfite conversion, PCR reactions, 
and pyrosequencing were also performed as previously 
described (Creemers et  al. 2016b). Briefly, after binding 
of the PCR product to streptavidin-coated Sepharose 
beads (GE Healthcare), the template was washed, made 
single-stranded and neutralized. Pyrosequencing assays of 
previously reported CpGs involved in the expression of 
IGF2 (DMR2, CTCF3 and the H19 promoter) were designed 
using Pyromark Assay Design. Pyrosequencing was 
performed using the PyroGold SQA reagent kit (Qiagen) 
according to manufacturer’s protocol and analyses were 
performed on the Pyromark Q24 system. DNA quality 
and quantity was assessed using the NanoDrop 2000c 
(ThermoFisher). PCR and corresponding sequencing 
primers are listed in Table 1.
Statistical analysis
Statistical analysis was performed using SPSS24 and 
Graphpad Prism 6.0. The methylation percentages in the 
three regions were transformed into a mean standard 
deviation score (SDS) compared to methylation in normal 
adrenals, as previously described (Creemers et al. 2016b). 
Correlation between parameters was assessed using the 
Spearman’s correlation coefficient. To assess significant 
differences in methylation between ACC and ACA, the 
non-parametric Mann–Whitney U-test was used.
Logistic regression analysis was used to assess the 
predictive value of the IGF2 methylation score for the 
pathological diagnosis of ACC, adjusted for tumor size. 
The Hosmer–Lemeshow test was used to evaluate the 
goodness of fit of the model. To determine a clinically 
relevant cutoff value for the methylation score and 
to assess the discrimination of the fitted logistic 
regression model, Receiver Operating Characteristic 
(ROC) curves were constructed, followed by calculation 
of the area under the curve (AUC). Hazard ratios (HR) 
for development of metastases during follow-up were 
estimated using Cox proportional hazards regression 
models. Time to metastasis was defined as the time from 
pathological diagnosis until the time metastasis occurred. 
The proportional hazards assumption was assessed with 
interaction of variables with time. Kaplan–Meier curves 
were constructed and compared using the Logrank 
test. In an attempt to resemble the clinical situation in 
which the methylation score could be valuable, patients 
with an already proven ACC at diagnosis, that is, with 
metastasized disease (ENSAT stage IV), were excluded 
from these analyses. For regression analyses, independent 
variables with a P less than 0.1 in univariate analyses were 
intended to be included in multivariate analysis. Data are 
presented as mean ± s.e.m., unless specified otherwise. A 




In total, 76 patients with ACC and 118 ACA patients were 
included from seven clinical specialist referral centers 
participating in ENS@T (Netherlands 3, Italy 2, Germany 
1, Spain 1; Table 2). From four centers, DNA isolated from 
snap-frozen specimens was collected, whereas from the 
remaining three centers frozen specimens were shipped to 
the coordinating center. The location at which the DNA 
isolation procedure was performed did not influence the 
results and the predictive value of the methylation score. 
Clinical and tumor characteristics of the patients included 
in this study are listed in Table 2.
The median tumor size was 10 cm for ACC and 
3.4 cm for ACA. The proportion of functional tumors (all 
hormones) was similar between ACC and ACA, whereas 
there was a clear difference between frequency of androgen 
and precursor secreting tumors, whose proportions were 
higher in ACC (both P < 0.0001 vs ACA). The proportion 
of mineralocorticoid overproduction was lower in ACC 
compared to ACA (P < 0.0001 vs ACA).
Of the tumors indicative of ACC on the basis of the 
WS, and with an available ENSAT stage (n = 66), 26% had 
metastasized disease at diagnosis (ENSAT stage IV) and 45% 
of tumors with follow-up data available and no metastases 
at diagnosis were clinically proven to be malignant by 
development of metastasis during follow-up. The patients 
with histological suspected ACC who did not metastasize 
at diagnosis or during follow-up had a median follow-up 
of 41.5 months (IQR 21.5–72.3).
Predictive value of the IGF2 methylation score for the 
pathological diagnosis of ACC
For all three regions, a different methylation pattern 
was observed for ACC compared to ACA (Fig. 1A, B and 
C). The IGF2 methylation score was significantly higher 
in ACC compared to ACA (Fig. 1D; P < 0.0001). Within 
ACC, no correlation was found between the methylation 
score and the WS (ρ = 0.017, P = 0.897). For analysis of the 
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diagnostic accuracy of the IGF2 methylation score for the 
pathological diagnosis of ACC and for the prediction of 
metastases development, confirmed ACC with metastases 
at diagnosis were initially excluded. The IGF2 methylation 
score and the tumor size appeared to be independently 
associated with the pathological diagnosis of ACC, with 
an OR of 3.756 (95% CI 2.224–6.343; P < 0.001) and 1.467 
(95% CI 1.202–1.792; P < 0.001), respectively (Table 3; 
Hosmer–Lemeshow test, P = 0.943).
The methylation score alone predicted the diagnosis 
on the basis of the WS (59 ACC, 118 ACA) with an AUC 
of 0.910 (Fig. 2A; 95% CI 0.867–0.953). When applying 
a cutoff value of 2.13 for the IGF2 methylation score, a 
sensitivity of 86% and a specificity of 84% was obtained 
for the pathological diagnosis of ACC. In case ENSAT stage 
III ACC were also excluded, an AUC of 0.898 (95% CI 
0.846–0.949) was obtained for discriminating ACC from 
ACA. ROC curve of the fitted logistic regression model 
including the IGF2 methylation score and tumor size 
resulted in an AUC of 0.957 (Fig. 2C; 95% CI 0.930–0.984).
Towards clinically useful cutoff values
To provide further insights into the discriminative 
performance of this quantitative test, sensitivity and 
specificity for different cutoff values are presented in Fig. 
2B. In this graph, we also demonstrate a zone that could 
be interpreted as a grey area, of which the implementation 
assures high diagnostic accuracy when the IGF2 methylation 
score is above or below this zone (Fig. 2B, striped area; 
score 1.28–3.15). Below the grey zone (<1.28), the negative 
predictive value is 97%, whereas a methylation score 
above the grey zone (>3.15) results in a positive predictive 
value of 87%. Tumors with a methylation score between 
1.28 and 3.15 should then be classified as inconclusive. 
Overall, in our series, 75 of the 118 ACA (64%) could be 
diagnosed as ACA with a sensitivity of 97% and thus had 
an IGF2 methylation score below 1.28. On the other hand, 
33 of the 59 ACC (56%) could be diagnosed as ACC with 
high diagnostic accuracy. Sixty-two tumors (35%) had a 
methylation score in the grey zone and were therefore 
classified as inconclusive diagnosis on the basis of the IGF2 
methylation score. Of these cases, 61% were classified as 
ACA based on the WS (median WS 0, IQR 0–0), whereas 
39% had a WS of 3 or more (median 6, IQR 3–8). Of 
the patients with clinically proven ACC as indicated by 
metastastic disease either at diagnosis or during follow-up, 
21 (58%) of the 36 were diagnosed as ACC according to 
the IGF2 methylation score, 2 as ACA, and 13 had an IGF2 
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When focusing on ACC with a WS of 3 in our series 
(n = 12), five appeared to have a methylation score above 
the grey zone and would therefore be classified as ACC 
according to the IGF2 methylation score. The other seven 
ACC with a WS of 3 would be classified as inconclusive 
diagnosis based on the methylation score. The median 
follow-up of patients with a tumor harbouring a WS of 
3 was 37 months (IQR 21–49), with one patient who 
developed metastasis after 21 months (IGF2 methylation 
score 1.66; grey zone). Of the six ACA with a WS of 2, four 
received a concluding diagnosis of an ACA on the basis of 
the methylations score, with a total median follow-up of 
5 months (IQR 0–22). The two other ACA cases had an 
IGF2 methylation score in the grey zone.
The predictive value of the IGF2 methylation score 
for malignancy as defined by metastatic ACC
As secondary outcome, we aimed to assess the predictive 
value of the IGF2 methylation score and other variables 
for predicting metastases. When tumors were divided into 
two groups based on the methylation score, a higher IGF2 
methylation score was associated with the development of 
metastases (Fig. 2D, P = 0.005). In univariate Cox regression 
analysis, not only the IGF2 methylation score but also 
the WS and tumor size were predictive for development 
of metastases (Total n = 118; 16 cases, 112 censored; 
Table 4). In multivariate analysis, however, only the WS 
was independently associated with metastatic disease 
(Table 4; HR 1.682, 95% CI 1.285–2.202, P < 0.001). The 
same finding was obtained when only ACC (total n = 53; 
16 cases, 37 censored) were included for both analyses: only 
the WS was independently associated with development 
of metastases (OR 1.443, 95% CI 1.050–1.984; P = 0.024).
Discussion
In this study, we externally validated the predictive value 
of methylation of IGF2 regulatory regions for the diagnosis 
of malignancy of adrenocortical tumors in a multicenter 
European cohort study and confirmed that the IGF2 
methylation score can serve as an objective diagnostic tool 
with a high sensitivity to detect adrenocortical malignancy.
Currently, the histopathological Weiss score is the most 
important diagnostic tool to establish adrenal malignancy. 
The WS harbours multiple challenges (Weiss et al. 1989, 
Aubert et  al. 2002), as its diagnostic applicability is low 
Table 2 Clinical and tumor characteristics of patients included in the present study.
All tumors, n = 194 ACC, n = 76 ACA, n = 118
Age at diagnosis, mean (years, range) 53 yrs (16–83) years 54 (23–83) years 53 (16–79) years
Sex (male, %) 77/194 (40%) 33/76 (43%) 44/118 (37%)
Tumor size (cm)
 Range 0.5–30 cm 2.1–30 cm 0.5–22 cm
 Mean 6.8 cm 11.6 cm 3.8 cm
 Median 5.0 cm 10.0 cm 3.4 cm
Steroid secretion
 Androgens 24/176 (14%) 21/69 (30%) 3/107 (3%)
 Glucocorticoids 88/180 (49%) 40/71 (56%) 48/109 (44%)
 Mineralocorticoids 32/180 (18%) 3/71 (4%) 29/109 (27%)
 Precursors 13/166 (8%) 13/66 (20%) 0/98 (0%)
 Estradiol 1/159 (1%) 1/61 (2%) 0/98 (0%)
 Non-secreting 47/175 (27%) 19/71 (27%) 28/104 (27%)
Weiss score
 Range 0–9 3–9 0–2
 Mean 2.5 5.8 0.31
 Median 1 6 0
ENSAT
 I - 8/66 (12%) -
 II - 25/66 (38%) -
 III - 16/66 (24%) -
 IV - 17/66 (26%) -
Metastasis during follow-up (n) 17/111 (15%) 17/38 (45%) 0/73 (0%)
Follow-up months, median (IQR) M1: 13 (4–24) M1: 13 (4–24) M1: -
M0: 27 (16–53) M0: 41.5 (21.5–72.3) M0: 23 (14.5–45.5)
For the data on follow-up, only patients with available follow-up data were included (ACA n = 73, ACC n = 38), and for the data concerning occurrence of 
metastases during follow-up, ENSAT tumor stage IV patients were excluded (n = 17).
ENSAT, European Network for the Study of Adrenal Tumors; M0, no metastases during follow-up; M1, metastases at diagnosis or during follow-up.
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among non-expert pathologists and a group of borderline 
cases with a WS of 2 or 3 exist with an uncertain outcome 
(Papotti et  al. 2011). Inter-observer agreement rates in 
previous studies are heterogeneous. In a study by Aubert 
and colleagues, a high inter-observer agreement was 
found for the total WS (r = 0.94) (Aubert et al. 2002). In 
another study using a virtual microscopy reading, a kappa 
statistic of 0.70 was obtained for the diagnosis of ACC in 
50 adrenocortical tumors scored by 12 pathologists (Tissier 
et al. 2012). The inter-observer reproducibility increased 
after a coaching meeting to a kappa statistic of 0.75 (Tissier 
et  al. 2012). It has thereby been shown in the German 
ACC registry that in 13% (n = 21/161) of cases a diagnosis 
of ACC had to be revised by a reference pathologist, also 
containing misdiagnosis of metastases from extra-adrenal 
cancers and pheochromocytoma (Johanssen et al. 2010). 
In addition, after histopathological review of a large 
Italian series it was demonstrated that the diagnosis was 
changed from ACC to ACA or vice versa upon review in 3% 
(n = 9/200) of the adrenocortical tumors (Duregon et  al. 
2015). Other disagreements were present in an additional 
17 cases in this study, concerning, in particular, the 
discrimination between ACC and pheochromocytoma or 
metastases (Duregon et al. 2015). Taking this into account, 
considering the retrospective design of the present study, 
this might have led to changes during follow-up in the 
current study as well. Studying new diagnostic tests is 
associated with important concerns and limitations, since 
diagnosis of adrenal malignancy is only definite in case of 
locoregional invasive tumor growth or metastatic disease 
and thus may require long-term follow-up. Consequently, 
the IGF2 methylation score is of particular interest in 
adrenocortical tumors with inconclusive diagnoses, that is, 
ENSAT stage I and II. The importance of studying accurate 
diagnostic tools for adrenal malignancy lies especially in 
the early decision on postoperative therapeutic strategies, 
that is, adjuvant treatment with mitotane, and prognosis 
stratification.
In recent decades, research has focused on epigenetic 
changes in ACC (Fonseca et  al. 2012, Barreau et  al. 
2013). Previously, these genome-wide approach studies 
were primarily used to identify subgroups of patients 
with ACC (Rechache et al. 2012, Creemers et al. 2016a), 
whereas the present study demonstrates a clinically useful 
cutoff value. Interest in the IGF2 gene originates from 
the association of ACC with the Beckwith–Wiedemann 
syndrome (Wiedemann 1983), and for over 20 years, 
IGF2 overexpression is the most frequently detected 
molecular alteration in ACC. IGF2 has also been shown 
to be an important factor for tumor growth in the 
majority of ACC cases (Guillaud-Bataille et al. 2014). The 




































































































Mean methylation percentages in the three IGF2 regulatory regions DMR2 
(A), CTCF3 (B), and the H19-promoter (C), and the IGF2 methylation score 
(D) for adrenocortical adenomas (ACA, n = 118) and carcinomas (ACC, 
n = 76). Every dot represents a patient. Lines represent medians with inter 
quartile range. DMR, differentially methylated region. ****P < 0.0001.
Table 3 Predictive value of the IGF2 methylation score and tumor size for the diagnosis of adrenocortical tumors on the basis of 
the Weiss score.
Univariate analysis Multivariate analysis
OR (95% CI) P-value OR (95% CI) P-value
IGF2 methylation score 4.954 (3.130–7.840) < 0.001 3.756 (2.224–6.343) < 0.001
Tumor size 1.733 (1.447–2.076) < 0.001 1.467 (1.202–1.792) < 0.001
The Weiss score as determined by the local pathologist was used, resulting in 57 ACC and 115 ACA. Patients with proven ACC at diagnosis, that is, 
metastatic disease, were excluded from analyses (n = 17). For this analysis, one outlier was excluded (ACA of 22 cm), but exclusion did not influence 
significance. Hosmer–Lemeshow test, P = 0.903. Bold indicates statistical significance.
OR, odds ratio.
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of instability or dysregulation of this system, explaining 
involvement in ACC. The IGF2 regulatory regions used 
in the previous study were identified on the basis of 
known associations with IGF2 expression or malignancy 
of adrenocortical tumors (Creemers et  al. 2016b). We 
have now externally validated the IGF2 methylation 
score in a multicenter European study. Together with the 
application of the WS as determined by the participating 
centers, this largely increases the generalizability of our 
findings. The performance of the IGF2 methylation score 
is high with a sensitivity and specificity of 86% and 84%, 
respectively, which is slightly less accurate compared 
to the previous study (Creemers et  al. 2016b). When 
we apply the threshold of 2.442 as determined in our 
first study, we found a sensitivity of 80% and a 
specificity of 90% in this fully independent set of tumors 
(Creemers et  al. 2016b). The most important advantage 
of the IGF2 methylation score as proposed in our study 
is that it is an easily applicable non-expensive objective 
measurement, which is not biased by inter-observer 
variability. Most quantitative diagnostic tests do not 
perfectly discriminate between groups of patients, often 
resulting in a significant overlap between distributions 
of test results for patients with and without a particular 
disease (Coste & Pouchot 2003). This also applies to the 
WS, where a score of 2 or 3 can be considered a grey zone 
(Pohlink et al. 2004a, Lau & Weiss 2009, Tissier 2010, de 
Krijger & Papathomas 2012). Although the diagnostic 
accuracy of the IGF2 methylation score is already high 
when applying one single cutoff value, we believe that 
the methylation score is especially useful when the value 
is below or above the grey zone as presented in this study 
Figure 2
Discriminative value of the IGF2 methylation score 
for discrimination between adrenocortical 
adenoma (ACA, n = 118) and adrenocortical 
carcinoma (ACC, n = 59). ENSAT tumor stage IV 
patients were excluded from analyses (n = 17). (A) 
ROC curve of the IGF2 methylation score for 
prediction of the pathological diagnosis of ACC. 
(B) Sensitivity and specificity for specific cutoff 
values of the IGF2 methylation score for the 
pathological diagnosis of ACC. The striped area 
represents a grey zone of the methylation score 
with less diagnostic accuracy. PPV and NPV for the 
cutoff value below (1.28) or above (3.18) the grey 
zone. (C) ROC curve of the logistic regression 
model including the methylation score and tumor 
size for predicting the pathological diagnosis of 
ACC. (D) Kaplan–Meier curve for two groups 
based on the IGF2 methylation score for 
development of metastases. The two groups were 
divided based on an IGF2 methylation score of 
2.45, which was based on the best discriminative 
value for the development of metastases 
calculated using ROC analysis. AUC, area under 
the curve; NPV; negative predictive value; PPV, 
positive predictive value; ROC, receiver operating 





























































































Patients at risk (n)
Low 76     51 24       13
High 52     33  18       14
P = 0.005
Table 4 Cox regression model for the development of metastases during follow-up.
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
IGF2 methylation score 1.380 (1.070–1.780) 0.013 0.861 (0.571–1.298) 0.476
Weiss score 1.702 (1.308–2.216) < 0.001 1.682 (1.285–2.202) < 0.001
Tumor size (cm) 1.110 (1.049–1.174) < 0.001 1.022 (0.940–1.111) 0.613
Patient age (years) 1.034 (0.996–1.074) 0.081 1.035 (0.988–1.083) 0.147
Patients with ENSAT tumor stage IV disease at diagnosis were excluded (n = 17). Patients for whom follow-up time was available were included in this 
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(65% of cases in this study), eventually assuring a higher 
diagnostic accuracy. This indicates, however, that the 
performance of the methylation score is lower in 35% 
of the cases with a value in the grey zone, which is a 
limitation of the clinical applicability.
In this study, we show that also in part of the cases 
with a WS of 3, which in clinical practice is interpreted 
as a less solid diagnosis of malignancy compared to 
a higher WS, a high IGF2 methylation score could 
potentially help to opt for toxic mitotane treatment. As 
demonstrated in this study, the diagnostic accuracy of the 
IGF2 methylation score improves when it is combined 
with tumor size. Further research could focus on the 
combination of the IGF2 methylation score with imaging 
characteristics, other clinical data or image analyses from 
histopathology, like the Ki67 index, in order to determine 
the optimal combination. These studies should also aim 
to further elucidate the diagnostic accuracy of the IGF2 
methylation score in the clinically most relevant group 
of adrenocortical tumors with a WS in the grey zone (WS 
of 2 or 3).
We have to acknowledge that this test is and will 
be applied to preselected adrenocortical tumors, with 
a relative high pre-test probability of malignancy. 
Adrenocortical tumors are surgically removed in case 
malignancy is suspected based on imaging characteristics 
or because of hormonal activity (Creemers et  al. 2015, 
2016a). In this respect, assessment of the urinary steroid 
metabolomic profile seems a promising new tool in the 
decision-making on surgery in patients with adrenal 
masses (Arlt et  al. 2011). To improve practicality and 
increase availability of samples, further research could 
focus on the possibility of these analyses in DNA isolated 
from formalin-fixed paraffin embedded tissues. Previous 
research has already shown that pyrosequencing of DNA 
isolated from FFPE tissues and snap-frozen specimens 
provides highly comparable results (Bock et al. 2016).
Besides the retrospective design, a limitation of 
this study is that we did not have access to executed 
pre-operative diagnostic tests, like various imaging 
techniques important for the decision on adrenalectomy. 
Another consideration is that patients with adrenal 
tumors classified as adenomas have shorter follow-up 
time compared to ACC patients, which makes it possible 
that development of metastases is underestimated in 
this group of patients. Development of metastases after 
years of follow-up have been previously reported in 
patients with a resected adrenocortical tumor originally 
classified as benign (Pohlink et al. 2004, Tan et al. 2005). 
In our study, the occurrence of metastases in the total 
group of patients probably represent underestimations, 
considering the median follow-up time of 27.5 months. 
Thereby, regarding our secondary aim, that is, the 
prediction of metastases occurring during follow-up, we 
acknowledge that the number of cases is very limited 
and the analyses should therefore be interpreted with 
caution. In univariate analyses, the IGF2 methylation 
score, the WS, and the tumor size were associated with 
the development of metastases. A limitation of this 
study is the lack of availability of the Ki67 index, which 
is to date the most important prognostic factor within 
ACC (Beuschlein et  al. 2015). In our study, the WS was 
the only independent predictive factor for metastases, 
although this might be affected by the limited statistical 
power due to a small sample size. Prospective studies are 
needed to further validate the diagnostic value of the 
IGF2 methylation score and evaluate the potential role in 
prediction of metastases.
In conclusion, we externally validated the high 
diagnostic accuracy of the previously proposed IGF2 
methylation score for confirming the pathological 
diagnosis of ACC in a multicenter European cohort 
study. Considering the known limitations in clinical 
applicability of the WS, the objective IGF2 methylation 
score could provide extra guidance to multidisciplinary 
teams on decisions regarding postoperative strategies in 
patients with adrenal masses.
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